Journal of Molecular Biomarkers & Diagnosis

ANXA7 Expression has Prognostic Impact for Patient Survival In Triple Negative Breast Cancers

Abstract

Meera Srivastava, Ofer Eidelman, Lukas Bubendorf and Harvey B. Pollard

Triple-negative breast cancers account for 10-17% of all breast carcinomas and there is considerable need for reliable prognostic markers to assist clinicians in making diagnostic and therapeutic management decisions. Altered ANXA7 (a novel pro-apoptotic tumor suppressor gene located on chromosome 10q21) protein levels are associated with a tumor-prone phenotype in knockout mouse model and prognostically challenging aggressive forms of prostate and breast cancer. So far, information is not available regarding the association of patient survival and ANXA7 expression in triple-negative breast cancers. Therefore, we used a retrospective prognostic tumor tissue microarray (TMA) technology in order to evaluate the ANXA7 immunoreactivity as a possible diagnostic and/ or prognostic marker of triple-negative breast cancer by immunoperoxidase assay using an ANXA7 monoclonal antibody. We report here that the expression of ANXA7 is significantly enhanced in triple-negative breast cancers and is associated with poor overall patient survival. We conclude that ANXA7 may be a new prognostic markers or a target for improving the treatment efficiency of patients with triple-negative breast cancers.